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Ischemic preconditioning 
for prevention of contrast-
medium-induced nephropathy: 
randomized pilot Renal 
Protection Trial
Er et al., Circulation 2012; 126: 296–303; doi:10.1161/
CIRCULATIONAHA.112.096370
Contrast-medium-induced acute kidney injury (CI-AKI) is one 
of the leading kinds of hospital-acquired AKIs and is associ-
ated with considerable morbidity and mortality. The underlying 
mechanism has been attributed partially to ischemic kidney 
injury. Ischemic preconditioning is the phenomenon whereby 
a prior ischemic insult renders the organ resistant to a subse-
quent ischemic insult. However, it may be unrealistic to induce 
ischemia of the native kidney before a procedure that will result 
in ischemia. Remote ischemic preconditioning is a more clini-
cally tractable therapeutic strategy by which protection can be 
afforded in one vascular bed by ischemia to another vascular 
bed in a different organ. It has been postulated that the remote 
organ releases humoral factors into the systemic circulation, 
which subsequently protect the remote organ. The authors per-
formed a randomized, double-blind, sham-controlled trial, the 
Renal Protection (RenPro) Trial, to assess the impact of remote 
ischemic preconditioning on CI-AKI. One hundred patients 
with impaired renal function undergoing coronary angiogra-
phy were randomized to standard care with or without remote 
ischemic preconditioning by intermittent arm ischemia. Both 
study groups were equal in their probability of developing 
CI-AKI on the basis of Mehran risk score. All patients in the 
study received oral N-acetylcysteine and continuous intrave-
nous saline infusion as a preventive measure. The primary end 
point was the incidence of CI-AKI, defined as an increase of 
serum creatinine of ≥25% and/or ≥0.5 mg/dl above baseline at 
48 hours after contrast-medium exposure. CI-AKI occurred in 
40% in the control group and 12% in the remote ischemic pre-
conditioning group (odds ratio 0.21, 95% confidence interval 
0.07–0.57). While seven patients required hemodialysis in the 
control group, none in the remote ischemic preconditioning 
group did so. The composite cardiovascular end point occurred 
in 38% in the control group and 16% in the remote ischemic 
preconditioning group. No major adverse events were related 
to remote ischemic preconditioning.
In conclusion, remote ischemic preconditioning before 
contrast-medium use prevented CI-AKI in high-risk patients. 
Thus, remote ischemic preconditioning may be a feasible and 
attractive therapeutic procedure.
Masaomi Nangaku
Vitamin K, bone fractures, 
vascular calcification,  
and mortality
Fusaro et al., J Bone Miner Res advance online publication, 12 June 2012, 
doi:10.1002/jbmr.1677
Vitamin K plays a major role in post-translational modifi-
cation via g-carboxylation of glutamate (Gla) residues, not 
only of coagulation factors but also of extrahepatic proteins 
involved in bone and vascular biology. The latter include 
bone-Gla-protein (BGP, also called osteocalcin) and matrix-
Gla-protein (MGP). BGP knockout mice develop hyperos-
tosis, and MGP knockout mice die from severe vascular 
calcification. In the general population, low dietary vitamin K 
intake is associated with low bone mineral density and frac-
tures. Dialysis patients are often vitamin K deficient and have 
uncarboxylated MGP (ucMGP), which is associated with 
cardiovascular disease. Fusaro et al. carried out an observa-
tional study in 387 chronic hemodialysis patients to further 
establish the prevalence of vitamin K deficiency and exam-
ine possible disease associations. Measurements of circulat-
ing phylloquinone (vitamin K1) and various menaquinone 
compounds (vitamin K2 (MK)) showed vitamin K deficiency 
varying from 14.5% to 35.4%, depending on the vitamin K 
compounds determined. Notably, in a study by Holden et 
al., vitamin K deficiency was present in 97% of chronic kid-
ney disease patients on the basis of serum levels of ‘proteins 
induced by vitamin K absence’ (PIVKA-II).1 In the report 
by Fusaro et al., serum ucMGP was threefold lower,  ucBGP 
elevenfold higher, total MGP twofold higher, and total BGP 
twelvefold higher in dialysis patients than in healthy subjects. 
Of the dialysis patients, 55.3% had vertebral fractures, 80.6% 
had abdominal aorta calcification, and 56.1% had iliac calci-
fication. Vitamin K1 deficiency was the strongest predictor 
of vertebral fractures. MK4 deficiency was a predictor of aor-
tic calcification, whereas MK5 deficiency, surprisingly, was 
protective against it. MK7 deficiency was a predictor of iliac 
calcification. The presence of vertebral fractures was also a 
predictor of vascular calcifications. There were no significant 
differences in plasma vitamin K1 or MK levels between non-
survivors and survivors. In contrast, increased serum total 
alkaline phosphatases, C-reactive protein, age, and cerebro-
vascular events were predictors of mortality risk.
Thus, vitamin K sufficiency may be important for preserving 
bone mass and avoiding vascular calcification in hemodialy-
sis patients. Now, prospective randomized trials are needed to 
prove or disprove any benefit of vitamin K supplementation.
Tilman B. Drüeke
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Corticosteroid therapy  
in IgA nephropathy
Lv et al., J Am Soc Nephrol 2012; 23: 1108–1116; doi:10.1681/
ASN.2011111112
Immunoglobulin A (IgA) nephropathy remains the most 
common cause of biopsy-proven primary glomerular dis-
ease in the world and frequently terminates in end-stage 
renal disease (ESRD). The spectrum of the disease process 
from the totally benign, microscopic hematuria that never 
changes to the full-blown, crescentic variant with rapidly 
progressive decline in renal function makes the assessment 
of therapies controversial and difficult. In particular, the use 
of corticosteroid therapy in this disorder has produced very 
mixed results and opinions. In this systematic meta-analysis, 
Lv et al. reviewed all published randomized controlled tri-
als from between 1966 and 2011, examining a total of 536 
patients from nine trials. In large part, these patients had nor-
mal renal function but more than 1 g of proteinuria per day, 
putting them in the category of higher risk of progression. 
The primary composite end point was restricted to kidney 
failure—defined as doubling of serum creatinine or halving 
of glomerular filtration rate or ESRD—which was found in 
approximately 9% of this population. Secondary end points 
assessed were reductions in proteinuria and adverse events. 
The analysis indicated that corticosteroid therapy was asso-
ciated with an overall decrease in risk of renal failure (2.5% 
versus 15%) as well as a reduction in proteinuria (mean dif-
ference of approximately 0.5 g/d between the steroid and no-
steroid groups). In their subgroup analysis, the authors found 
that only high-dose, short-term steroids conferred a benefit 
on these end points; the more prolonged, lower-dose corti-
costeroid regimens had no benefit. Another distinguishing 
feature of the analysis is that the frequency of adverse events 
was also assessed. As expected, steroid therapy was associ-
ated with a significant (55%) incidence of adverse events, 
although most were related to weight gain and development 
of cushingoid features.
There are problems associated with any meta-analysis. 
The authors admit that the quality of the trials examined 
was not high, and the difficulty of generalizing the conclu-
sions reduces their strength. The authors suggest the need 
for a large randomized controlled trial to test the efficacy of 
corticosteroids in reducing renal failure in IgA patients at 
high risk of disease progression.
Daniel Cattran
Hydroxyethyl starch 130/0.42 
versus Ringer’s acetate  
in severe sepsis
Perner et al., N Engl J Med 2012; 367: 124–134; doi:10.1056/
NEJMoa1204242
Intravenous fluid resuscitation is the mainstay treatment for 
patients with severe sepsis. However, the type of intra venous 
fluids to use remains controversial. The Surviving Sepsis 
Campaign guidelines recommend the use of colloid or crystal-
loid solutions, whereas the recent Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines recommend crystalloid 
rather than colloid. The lack of consensus is due to prior con-
flicting reports. Older preparations of hydroxyethyl starch (HES) 
(heta-, hexa-, and pentastarch) have been shown to impair renal 
function and hemostasis. Three large trials using a hyperoncotic 
HES, HES 200/0.5–0.6 (molecular weight in kDa/substitution 
ratio – hydroxyethyl groups per glucose molecule), found diver-
gent results with regard to acute kidney injury. The efficacy of 
newer lower-molecular weight formulations with fewer substitu-
tions, such as HES 130/0.42, in sepsis is not known. Perner et al. 
for the 6S Trial Group and the Scandinavian Critical Care Tri-
als Group performed a multicenter, parallel-group, blinded trial 
in which patients with severe sepsis were randomized to fluid 
resuscitation in the intensive care unit with 6% HES 130/0.42 or 
Ringer’s acetate. The study population was derived from 26 inten-
sive care units in Denmark, Norway, Finland, and Iceland. The 
primary outcome was death or dialysis depen dency (end-stage 
renal disease) at 90 days after randomization. Eight hundred four 
patients were randomized to two intervention groups with simi-
lar baseline characteristics. The results showed that more patients 
in the HES 130/0.42 than in the Ringer’s acetate group died (51% 
versus 43%), were treated with renal replacement therapy (22% 
versus 16%), or had severe bleeding episodes (10% versus 6%). 
The increase in adverse events observed with HES 130/0.42 may 
be due to the effects on coagulation, toxicity due to tissue accu-
mulation, or other mechanisms. Interestingly, despite the general 
agreement that colloids are better plasma volume expanders, 
there was no difference in trial-fluid volume administration, rais-
ing concern regarding the efficacy of HES 130/0.42 relative to 
Ringer’s acetate as a plasma volume expander in severe sepsis. An 
important limitation is the unavailability of hemodynamic data. 
This study, consistent with others, indicates that HES 130/0.42 is 
not better than Ringer’s acetate for the treatment of severe sepsis 
and may be more harmful.
Mark Okusa
